Imi Medical Innovations (AMEX:IME)
Historical Stock Chart
From Jul 2019 to Jul 2024
IMI to Present at 16th Annual Wall Street Analyst Forum in New
York
TORONTO, Feb. 16 /PRNewswire-FirstCall/ -- Predictive medicine company IMI
International Medical Innovations Inc. (TSX:IMI; Amex: IME) today announced
that management will present IMI's investment highlights to analysts and
investors at the 16th Annual Wall Street Analyst Forum on Wednesday, March 2,
2005 at 9 a.m. ET at The Roosevelt Hotel, located on Madison Avenue at 45th
Street, in New York.
President and Chief Executive Officer Dr. Brent Norton will provide an update
on the company's recent accomplishments and business strategy.
"IMI is a growing company with tremendous prospects, and we look forward to
communicating that message to the audience at this event," said Dr. Norton. "We
recently announced that our lead cardiovascular product, PREVU(x) Point of Care
Skin Sterol Test, is now available for sale to the North American professional
medical community. Additionally, exciting new data on skin sterol testing will
be presented at the upcoming American College of Cardiology annual meeting. We
have also been notified that three new clinical papers on skin sterol have been
accepted for publication this year by various peer-reviewed journals. Fiscal
2005 is off to a very successful start and we expect the momentum to build
throughout the year."
A live webcast of Dr. Norton's presentation and accompanying slides will be
available on IMI's website at http://www.imimedical.com/ and subsequently
archived for a period of 30 days.
The Wall Street Analyst Forum has been a leading independent sponsor of analyst
conferences in New York, Boston and London since 1989.
About IMI
IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases. IMI's
cardiovascular products, branded as PREVU(x) Skin Sterol Test, are marketed and
distributed worldwide by McNeil Consumer Healthcare. The company's cancer tests
include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. IMI's head
office is located in Toronto, and its research and product development facility
is at McMaster University in Hamilton, Ontario. For further information, please
visit http://www.imimedical.com/.
This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the lack of
operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, the
successful development or marketing of the Company's products, reliance on
third-party manufacturers, the competitiveness of the Company's products if
successfully commercialized, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the protection
offered by the Company's patents and patent applications may be challenged,
invalidated or circumvented by our competitors and there can be no guarantee of
our ability to obtain or maintain patent protection for our products or product
candidates.
Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. IMI is providing
this information as of the date of this press release and does not undertake
any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
DATASOURCE: IMI International Medical Innovations Inc.
CONTACT: Company Contact, Sarah Borg-Olivier, Director, Communications,
T: (416) 222-3449, ; U.S. Investor Contact:
Andrea Faville, The Investor Relations Group, T: (212) 825-3210,